The expansion of the SomaScan 11K Platform followed accredited quality assurance standards at SomaLogic, including ISO 9001:2015, ISO 15189:2012 and ISO 27001:2013.

The SomaScan Platform is for Research Use Only (RUO) and has not been cleared or approved by the U.S. Food and Drug Administration for diagnostic or patient management purposes.

SomaLogic Inc., a Boulder-based biotechnology company, has licensed its SomaScan protein-diagnostics platform to Israeli life-sciences firm OncoHost Inc.

Discover more with the first and only technology that can measure 7,000 proteins over a broad range of concentrations. Built on 20 years of pioneering proteomics technology, The SomaScan Assay enables ...

BOULDER, Colo., Dec. 07, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today the full-scale global launch of the SomaLogic™ Certified Site program, which ...

The SomaScan Discovery Platform can analyze 7000 proteins in just 55 microL of the blood sample, over 3.5x than the competition.

The expansion of the SomaScan 11K Platform followed accredited quality assurance standards at SomaLogic, including ISO 9001:2015, ISO 15189:2012 and ISO 27001:2013.